UCLA researchers have developed a novel flexible balloon-inflatable electrochemical impedance spectroscopy to facilitate the diagnosis of metabolically active atherosclerotic lesions.
Identifying metabolically active atherosclerotic lesions remains an unmet clinical challenge during coronary intervention. Detection of atherosclerotic lesions prone to rupture is of utmost importance in the management of patients with myocardial infarction and stroke. Atherosclerotic plaques usually contain high levels of inflammatory activity, due to oxidized lipids and foam cells. Predicting metabolically active atherosclerotic lesions has remained an unmet clinical need. A solution to this need is the use of electrochemical impedance spectroscopy (EIS) for detecting frequency-dependent changes in tissue impedance.
UCLA researchers have developed a novel electrochemical impedance spectroscopy (EIS) sensor for the detection of atherosclerotic lesions. This sensor is flexible, stretchable, biocompatible (parylene-based) in design, and can be used with standard cardiovascular balloon catheters used in the clinic. It can provide real-time identification of atherosclerotic lesions in situ and detect oxLDL-rich regions by distinguished patterns of readout impedance magnitudes.
The method has been demonstrated ex vivo and in vivo.
Electrochemical impedance spectroscopy (EIS), atherosclerotic lesions, cardiovascular disease, atherosclerosis, catheter, Cardiovascular surgical devices, intravascular sensing, atherosclerosis, coronary heart disease, atherosclerotic plaque detection, balloon angioplasty, catheter ablation, electrochemical impedance spectroscopy